Gfb-887 ic50
WebOct 22, 2024 · -- GFB-887, a first-in-class highly potent and selective inhibitor of the TRPC5-Rac1 pathway, was well-tolerated in single ascending doses -- -- GFB-887 induced dose … WebMay 31, 2024 · A First-In-Human, Phase 1, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GFB-887, a TRPC5 Channel Inhibitor, in Healthy Subjects: Actual Study Start Date : May 29, 2024: Actual Primary Completion Date : March 4, 2024: Actual Study Completion Date :
Gfb-887 ic50
Did you know?
WebJul 8, 2024 · We performed pharmacokinetic (PK) studies with GFB-887, an investigational new drug now in phase 2 trials. Orally dosed GFB-887 to athymic rats that had … WebFeb 2, 2024 · “GFB-887 demonstrated compelling benefits in preclinical models of mood and anxiety disorders, and we are delighted that Karuna will leverage its well-established expertise in developing medicines for psychiatric disorders to advance our TRPC4/5 candidates,” commented Anthony Johnson, M.D., president and chief executive officer of …
WebNational Center for Biotechnology Information WebJun 25, 2024 · This is an open-label Phase 2 study evaluating the long term safety and tolerability of GFB-887 in patients with focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change disease (TR-MCD) Study Overview Status Terminated Conditions Kidney Diseases Glomerulonephritis Nephritis Nephrosis Glomerulosclerosis
WebGFB-887 is a sub-type selective, small molecule TRPC5 ion channel inhibitor that has been shown in preclinical models to prevent podocyte damage mediated by Rac1 activation. … WebFeb 6, 2024 · GFB 887 is an orally bio-available, sub-type selective, small molecule, TRPC5 ion channel inhibitor, being developed by Goldfinch Bio, for the treatment of GFB 887 - …
WebJun 23, 2024 · Goldfinch Bio’s TRACTION-2 clinical research trial is evaluating an investigational precision medicine, GFB-887, for the potential treatment of TRMCD and FSGS. The purpose of the trial is to determine if GFB-887 is safe and may help people who have high levels of protein in their urine due to kidney diseases caused by podocyte injury.
WebJun 25, 2024 · An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases. November 10, 2024 updated by: Goldfinch Bio, Inc. This is an open … chilling adventures of sabrina gamesWebJul 1, 2024 · GFB-887 is a podocyte-targeting, small molecule inhibitor of transient receptor potential canonical-5 (TRPC5) designed specifically to treat patients with glomerular … chilling adventures of sabrina judasWebFeb 2, 2024 · "GFB-887 demonstrated compelling benefits in preclinical models of mood and anxiety disorders, and we are delighted that Karuna will leverage its well-established … chilling adventures of sabrina greendaleWebFeb 2, 2024 · Researchers have suggested that targeting brain TRPs could be a useful approach to developing therapeutics for psychiatric and neurogenerative disorders. GFB-887 was developed by Goldfinch to treat patients with kidney disease. The company announced positive results from the Phase II trial in February 2024. chilling adventures of sabrina idlixWebAug 10, 2024 · GFB-887 is a once-daily, oral TRPC5 ion channel inhibitor in clinical development for the treatment of kidney diseases, including FSGS, TR-MCD and DN. TRPC5 is a calcium-permeable ion channel... chilling adventures of sabrina lupercaliaWebWe have designed a molecule, GFB-111, that binds to platelet-derived growth factor (PDGF), prevents it from binding to its receptor tyrosine kinase, and blocks PDGF … chilling adventures of sabrina free downloadWebFeb 2, 2024 · “GFB-887 demonstrated compelling benefits in preclinical models of mood and anxiety disorders, and we are delighted that Karuna will leverage its well-established expertise in developing medicines for psychiatric disorders to advance our TRPC4/5 candidates,” commented Anthony Johnson, M.D., president and chief executive officer of … grace louchheim